These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6739373)

  • 81. Cancer of the prostate. Treating metastasis with estramustine phosphate.
    Hoeft RT; Jones AG
    Am J Nurs; 1982 May; 82(5):829-30. PubMed ID: 6918193
    [No Abstract]   [Full Text] [Related]  

  • 82. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
    Kalland T; Haukaas S
    Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Control of response to estramustine phosphate therapy through cytology and DNA analysis of cell nuclei in prospective study.
    Leistenschneider W; Nagel R
    Urology; 1984 Jun; 23(6 Suppl):81-8. PubMed ID: 6730143
    [No Abstract]   [Full Text] [Related]  

  • 84. [Value of estramustine phosphate in the treatment of estrogen-resistant prostatic adenocarcinoma].
    Toulouse J; Jung JL; Bittard M
    J Urol (Paris); 1984; 90(1):27-33. PubMed ID: 6725973
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Hormonal treatment of cancer of the prostate].
    Aguiló F; Torrecilla C; Muñoz J; Tesedo X; Vigués F; Serrallach N
    Actas Urol Esp; 1989; 13(4):256-63. PubMed ID: 2678937
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Estramustine phosphate in secondary hormone-resistant carcinoma of the prostate.
    Maier U; Hienert G; Simak R
    Eur Urol; 1990; 17(3):216-8. PubMed ID: 2351191
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation.
    Murphy GP; Gibbons RP; Johnson DE; Prout GR; Schmidt JD; Soloway MS; Loening SA; Chu TM; Gaeta JF; Saroff J; Wajsman Z; Slack N; Scott WW
    Trans Am Assoc Genitourin Surg; 1978; 70():69-71. PubMed ID: 753026
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Treatment of advanced estrogen-resistant cancer of the prostate with estramustine phosphate. A phase-2 study].
    Trykker HU
    Ugeskr Laeger; 1985 Oct; 147(42):3310-2. PubMed ID: 4082315
    [No Abstract]   [Full Text] [Related]  

  • 89. Metabolism of estramustine phosphate (Estracyt) in patients with prostatic carcinoma.
    Andersson SB; Gunnarsson PO; Nilsson T; Forshell GP
    Eur J Drug Metab Pharmacokinet; 1981; 6(2):149-54. PubMed ID: 7274309
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Estramustine phosphate: metabolic aspects related to its action in prostatic cancer.
    Kadohama N; Kirdani RY; Murphy GP; Sandberg AA
    J Urol; 1978 Feb; 119(2):234-9. PubMed ID: 633484
    [TBL] [Abstract][Full Text] [Related]  

  • 91. New steroidal alkylating agents in advanced stage D carcinoma of the prostate.
    Mittelman A; Catane R; Murphy GP
    Cancer Treat Rep; 1977; 61(2):307-10. PubMed ID: 872134
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Treatment of stage D hormone-resistant carcinoma of the prostate with estramustine phosphate.
    Benson RC; Wear JB; Gill GM
    J Urol; 1979 Apr; 121(4):452-4. PubMed ID: 439216
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Palliative treatment with oral Estracyte in disseminated prostatic carcinoma.
    Welvaart K
    Arch Chir Neerl; 1975; 27(3):193-8. PubMed ID: 55103
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Drug therapy of prostatic cancer.
    Benson RC; Utz DC; Murphy GP
    Urology; 1982 Jun; 19(6):621-2. PubMed ID: 7046189
    [No Abstract]   [Full Text] [Related]  

  • 95. Inhibitory effects of Estracyt on R-3327 rat prostatic carcinoma.
    Müntzing J; Kirdani RY; Saroff J; Murphy GP; Sandberg AA
    Urology; 1977 Nov; 10(5):439-45. PubMed ID: 919134
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Pharmacoclinical study of oral estramustine phosphate (Estracyt) in advanced carcinoma of the prostate.
    Müntzing J; Shukla SK; Chu TM; Mittelman A; Murphy GP
    Invest Urol; 1974 Jul; 12(1):65-8. PubMed ID: 4835492
    [No Abstract]   [Full Text] [Related]  

  • 97. Estramustine phosphate in the treatment of advanced prostatic cancer.
    Küss R; Khoury S; Richard F; Fourcade F; Frantz P; Capelle JP
    Br J Urol; 1980 Feb; 52(1):29-33. PubMed ID: 7426949
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Continuous versus intermittent oral therapy with estramustine phosphate (Estracyt).
    Vahlensieck W; Wegner G
    Scand J Urol Nephrol Suppl; 1980; 55():147-9. PubMed ID: 6938018
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Estracyt therapy in advanced prostate cancer: current status and personal results].
    Nagel R; Leistenschneider W
    Urologe A; 1983 May; 22(3):162-6. PubMed ID: 6683899
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Clinical experimental randomized study of 2.6-cis-diphenylhexamethylcyclotetrasiloxane and estramustine-17-phosphate in the treatment of prostatic carcinoma.
    Edsmyr F; Esposti PL; Johansson B; Strindberg B
    J Urol; 1978 Dec; 120(6):705-7. PubMed ID: 731810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.